The Food and Drug Administration approved the first needle-free alternative to the EpiPen on Friday, a single-use epinephrine nasal spray for the emergency treatment of allergic reactions, including anaphylaxis.

…

Aside from being needle-free, part of the appeal of the device is that it could provide competition to the expensive EpiPen.

In 2007, a pack of two injectors cost $100, but when Mylan bought the product, it hiked the cash price to more than $600 by 2016 — despite each pen costing a fraction of that to make.

As a result of the outcry, Mylan began selling an “authorized generic” for $300. An authorized generic is essentially the same product as the brand-name drug, just marketed without the brand name.

For people with severe allergic reactions who have commercial insurance that covers Neffy, ARS said it will use a copay savings program to limit the cost to $25 for each filled prescription of two single-use Neffy devices.